High throughput technologies, such as gene expression arrays and protein mass spectrometry, allow one to simultaneously evaluate thousands of potential biomarkers that distinguish different tissue types. Of particular interest here is cancer versus normal organ tissues. We consider statistical methods to rank genes (or proteins) in regards to differential expression between tissues. Various statistical measures are considered and we argue that two measures related to the Receiver Operating Characteristic Curve are particularly suitable for this purpose. We also propose that sampling variability in the gene rankings be quantified and suggest using the 'selection probability function,' the probability distribution of rankings for each gene. This is estimated via the bootstrap. A real data set derived from gene expression arrays of 23 normal and 30 ovarian cancer tissues are analyzed. Simulation studies are also used to assess the relative performance of different statistical gene ranking measures and our quantification of sampling variability. Our approach leads naturally to a procedure for Hosted by The Berkeley Electronic Press sample size calculations appropriate for exploratory studies that seek to identify differentially expressed genes.
Introduction
The development of microarrays that provide simultaneous evaluation of mRNA expression levels for thousands of genes is one of the exciting new advances in modern medical research. It promises to identify disease at its most basic biological level, namely at that of the genes. The implications for medicine are considerable (The Chipping Forecast, 1999) . Insights into genetic alterations caused by disease can lead to new therapeutic strategies. Genetic alterations that precede disease can be targets for disease prevention strategies. The research community can expect insights into the etiology of disease and pathways involved in its progression, that may well revolutionize medical practice.
There are new statistical challenges posed by data from microarray experiments, due primarily to the exploratory nature of experiments and the huge numbers of genes under investigation. It must also be recognized that different sorts of questions are addressed with microarray experiments and that the appropriate statistical approach depends, of course, on the question of interest (Dudoit et al, 2000) . Categories of objectives pertaining to experiments that include multiple tissue types (e.g. cancer versus non-cancer tissue) include: i) selection of genes that are differentially expressed in different known classes of tissue; (ii) identification of a minimal combination of genes that provides discrimination between known tissue types; (iii) identification of groups of genes whose expression levels are correlated; and (iv) new classifications of tissue types defined by genes whose expression levels are related. Statistical techniques such as regression methods and discriminant analyses have been adapted for (ii) (Dudoit et al, 2000) , whereas clustering techniques are more appropriate for (iii) and (iv) , Lazzeroni and Owen, 2002 , Van Der Laan and Bryan, 2001 .
In this paper we consider statistical methods for objective (i), which, at first glance, seems to be the most straight-forward.
The particular application that motivated our work concerns the search for biomarkers of ovarian cancer that could be used in population screening. Ovarian tissue from 30 subjects with cancer and 23 subjects without cancer were analyzed for mRNA expression using glass arrays spotted for 1536 gene clones. The data, Y , for the g ig th gene clone in the i th tissue sample, is a measure of the mRNA expression of the g th gene in that tissue relative to a control tissue, with a common control employed for all experiments. We refer to Dudoit et al. (2002) and Newton et al. (2000) for a simple summary of this technology and a technical explanation for how Y is calculated. Schummer et al. (1999) describe their data processing algorithms that are similar to those used to arrive at the relative expression values in the ovarian cancer study. Using standard terminology for these experiments, Y is the logarithm of the ratio of the intensities of the red to green ig ig fluorescent dyes, where green dye is used for the common control and red is used for the experimental tissue.
The scientific objective is to identify genes that are differentially expressed in ovarian cancer tissue compared with normal ovarian tissue. Ovarian tissue cannot of course be used directly for population screening. However, if a gene is found that is expressed differentially in cancer tissue, then the corresponding protein product (or an antibody to it) may be detectable in blood or urine and could be the basis for a population screening test. We refer to Pepe et al (2001) for discussion of the phases of biomarker development from the initial exploratory phase that we discuss here to its application in population screening programs. In general, scientists are more interested in identifying genes that are over-expressed rather than under-expressed in cancer screening research. This is because detecting the presence of a new aberrant protein in blood is a potentially easier task than detecting the reduced level of a normal protein, particularly if that protein is also produced by normal organ tissue in the body of the patient with cancer. Therefore in this paper we focus on detection of over-expressed genes although adaptation of the methods to detection of under-expressed genes is obvious.
There are many genes over-expressed in cancer tissue that cannot lead to screening markers. For example, genes that relate simply to inflammation or growth are not candidates because those processes also occur naturally in the body. Clinical assays for some gene products may be too difficult to develop for technical reasons. Therefore we need to select a sizeable number of over-expressed genes in order to arrive at a subset that might have potential for screening. For the initial selection, we will include multiple genes that are redundant in the sense that they identify the same cancer samples so that if one gene proves useless for biomarker development we can still pursue another that could identify those same cancers.
The experimental data are used to rank candidate genes according to some statistical measure characterizing differential expression. In section 2 we discuss the choice of statistical measure. A method for quantifying the degree of confidence in the ranking of a gene provided by the data is proposed is section 3. This acknowledges the finite number of tissues examined, variability across tissues and the large number of genes investigated, all of which contribute to uncertainty in the ranking of the genes. Application to the ovarian cancer data in section 4 illustrates the approach. One approach to computing sample sizes in these exploratory studies is suggested in section 5. Some further remarks about experimental design are made in section 6. We close with some thoughts on further extensions of our proposed methods.
Characterizing Interesting Differential Expression

Measures of Discrimination
At each gene, data are available for n D cancer tissues and n C normal tissues.
, 1,..., . , 1, ..., (Bamber, 1975) . Each of ROC , pAUC and AUC are distribution free rank statistics whereas Zstat depends on the underlying probability distributions for
Illustration
To illustrate our ideas we consider a small dataset comprising the first 100 genes in our ovarian cancer dataset. Table 1 displays the top 10 ranking genes in order when ranked according to the different statistical measures. Later we will return to the larger dataset.
For illustration purposes, we chose a smaller set here because this provided substantial variation in the discrimination capacities of the top 10 genes while the top 10 genes from the larger pool of genes were less varied.
Turning to Table 1 we see that to a large extent the same genes were identified by all discrimination measures, although the order of ranking differed. Consider, however, genes 5 and 97 for which raw data and ROC curves are displayed in Figure 3 . The MannWhitney U-statistic (AUC) ranked these genes very similarly, as the 6 th and 8 th ,
respectively. On the other hand, the pAUC statistic ranked them quite differently as the indeed for gene 5 more of the cancer tissues are above the bulk of the normative range than is the case for gene 97. The pAUC statistic picks up on this fact and gives it a far higher rank than it gives gene 97. It suggests to these authors that gene 5 should receive higher priority for biomarker development than gene 97.
Insert Table 1 2.3 Additional steps for selection.
The main point we wish to make in this section is that careful consideration of the statistical measure used to rank genes in regards to differential expression is warranted in applications. In disease screening, ROC or pAUC measures are proposed. The ranking is of course only one step in the process of selecting genes for further study. One will investigate the actual separation achieved between the distributions of
genes that rank well. ROC curves such as shown in Figure 3b should be considered in this evaluation because they display the separation achieved on a scale that is relevant to the problem and that allows for direct comparisons between genes. It is more difficult to compare genes using frequency distributions of the raw expression data ( Figure 3a ).
The next step towards selecting genes for further experimental work is to investigate
what is already known about the function of the genes that appear to have promising differential expression. Libraries of information are available from the public and private domains. Genes may be eliminated from further investigation for a variety of reasons related to their known function or prior experience with assay development. Investigators then select some set of genes for further investigation. The number depends on multiple factors, not the least of which is the resources available for experimental work.
In this paper we focus on the initial step in the gene selection process, namely the ranking step that orders genes in regards to a statistical measure of differential expression. In section 3 we discuss the sampling variability in the rank ordering. Related to this, in section 5 we propose that the achievement of adequate rank ordering be a basis for choosing sample sizes in these studies. In particular we propose that the study design should ensure that genes with promising differential expression should rank high and therefore be drawn to the attention of the investigators.
Assessing Variability
3.1 The probability of gene selection.
The relative rankings of genes is the primary outcome of the study. However, the rankings are subject to sampling variability. How should this variability be acknowledged? Standard errors or p-values don't seem to be directly relevant to the task because the stated objective is neither to estimate parameters nor to test hypotheses.
Rather, the task is to rank genes and to select the top genes for further study. Therefore we propose the following quantity to quantify our degree of confidence in choosing the g th gene among the top k.
The value of may be of particular interest for k equal to a predetermined number of genes to be selected (10 in the small illustration). However, the whole survivor function can be considered, { (
, and this gives a more full description of sampling variability in the ranking. Various factors contribute to the variability in Rank(g): (i) the number of cancer tissues and normal tissues studied, and ; (ii) the extent and type of differential expression of the g
th gene; (iii) the number of genes in the selection pool, which we denote by N; (iv) the differential expression of genes other than the g th gene; and not least, (v) the algorithm or statistical measure used to rank genes. The quantity, , will be affected by all of these factors.
g Intuitively, as sample sizes increase, the function will tend to 0 or 1 for differentially expressed genes according to whether the true asymptotic discriminating measure for the g ( ) g P k th gene ranks below or not. Genes that in truth are very highly discriminatory will certainly have high ranks even in experiments with small sample sizes and will be close to 1. This may be reduced by chance if there is a large number of competing genes and in particular if a substantial number of competing genes also exhibit differential expression. Observe that at the opposite extreme, if no genes are differentially expressed, then . This was done in an effort to make the bootstrap distribution of the rank statistics more reflective of the actual distribution across different realizations of the experiment.
Illustration
Returning to the small illustration described earlier, Table 1 Reiser and Guttman, 1986) . Data for different genes were generated independently. We set the number of genes to be selected at . Table 2 panel A shows the proportions of informative markers selected averaged across 100 simulation studies. That is, it shows P[Rank(g)≤k│g is an informative gene].
Insert table 2
The results suggest that the top 100 genes consist primarily of informative genes even with relatively small sample sizes. An informative gene has a 68% chance of being in the top 100 ranked on the basis of the pAUC(0.2) statistic when 30 samples are analyzed, 15
cancer and 15 normal tissues. The chance reaches 91% when a total of 35 cancer and 35 normals are evaluated.
In this particular example, (setting A of Table 2 ), the pAUC statistic was most effective at selecting informative genes. Interestingly it outperformed the full area under the curve the AUC statistic. That is, focusing on differences between the normal and cancer tissues only in the upper end of the normative range, yielded a better selection algorithm. This will not always be the case. In another set of simulations (also shown in Table 2 ) where informative genes had a mean 1 and standard deviation 1 in cancer tissues compared with standard normal in non-cancer tissues, the AUC statistic performed better.
These simulations assume statistical independence of genes and hence are unlikely to reflect real data. In practice one might find that subsets of informative genes are correlated statistically, and likewise subsets of uninformative genes are correlated.
Intuition suggests that this would lead to higher selection probabilities for informative genes than those in Table 2 because correlated genes will behave as a unit and reduce variability compared with the setting where all genes are independent. We will return to simulation studies later when we consider sample size calculations.
Analysis of the Full Ovarian Cancer Dataset
The 1536 genes spotted on the glass arrays were ranked according to each of the discriminatory statistics defined above. Sixty-five genes were ranked in the top 100 by all 4 ranking statistics while 16 genes were selected among the top 100 by only one of the statistics (7 by ROC (0.10), 9 by pAUC (0.10), 0 by AUC and 0 by Zstat only).
The stability of their selection, quantified by P g (100), was estimated with 200 bootstrap samples. Figure 4 displays the results. The selection probabilities for the AUC and Zstat statistics are overall higher than those for the pAUC (0.10) and ROC (0.10) statistics.
This presumably indicates less variability in the statistics that use more of data, namely AUC and Zstat. The selection algorithms based on them therefore are less variable and more reproducible across experiments. However, we saw earlier ( Table 2 ) that this does not necessarily induce higher sensitivity to differential expression and in particular to the sorts of differential expression of most interest to biologists.
Another display of the resampling results, specifically for the pAUC (0.1) statistic, is shown in Figure 5 . (Kataoka et al., 2000) ; TACSTD1, an adenocarcinomaassociated antigen, is currently being used in a clinical trial as a target in the treatment of gastro-intestinal carcinomas (Staib et al., 2001 ); HE4 is a potential ovarian cancer marker (Schummer et al., 1999) , which is currently being evaluated in a serum assay (unpublished results); oviductal glycoprotein has a role in fertilization (Verhage et al., 1997) and was found to be expressed at higher levels in ovarian carcinomas (unpublished results); and Keratin 8 expression is associated with cervical cancer progression (Smedts et al., 1990) . Moreover, one of the two EST-related clones is homologous to a putative integral membrane transporter protein discovered in hepatocellular carcinoma (NCBI website http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=retrieve&db=Nucleotide &list_uids=7320864&dopt=GenBank).
http://biostats.bepress.com/uwbiostat/paper184
With five of six top-ranking genes known to be related to cancer, our biologist colleagues are motivated to study further the remaining 3 genes with unknown function. They suspect that those genes may be tumor-related as well. This of course remains to be seen.
Of the top 10 genes selected according to the pAUC(.1) statistic, 6 were also ranked in the top 10 by the AUC statistic. The 4 additional genes ranked in the top 10 by AUC included one with unknown function, one that relates to a brain protein not found in normal ovary, one "housekeeping genes" involved in glycolysis and one (IFI27) that has been found to be overexpressed in breast carcinomas. The last two were ranked 28 and 30, respectively, with the pAUC(.1) statistic having values that were approximately 64% of the ideal value of 0.1. In contrast the 9 th and 10 th ranking genes according to the pAUC(.1) algorithm were 80% of the ideal value.
Sample Size Calculations
Gene expression microarray experiments are expensive. Therefore in practice sample sizes tend to be small. Our simulation study and analysis of the ovarian cancer dataset nevertheless, suggested that an informative analysis, properly accounting for sampling variability, can be based on experiments with relatively small sample sizes. This initially seemed surprising to us, but in retrospect it is intuitively reasonable. Informative genes will show themselves to be so even with small sample sizes.
What advice can the statistician offer for choices of sample sizes in exploratory gene expression studies? Since the task is to select informative genes from the pool of genes studied, the criterion for choosing sample sizes should be that they be large enough to ensure that informative genes have a high chance of being selected for further study on the basis of data from the experiment. Again, traditional notions of basing sample size calculations on hypothesis tests or on precision of estimators seem inappropriate.
Suppose that resources exist such that the top ranked genes will be considered for further study, , say. The sample size might be driven by the requirement that an informative gene, ranking in truth in the top genes (
, has a probability of at least β of being ranked in the top in the experiment. That is, the investigator suspects that a gene that ranks in the top k 0 k 1 will be of interest and wants to be assured that such a gene will be identified in the experiment. Therefore, one might choose and so that To calculate we suggest that a simulation study be performed. In fact the simulation study described in section 3.3 was our first attempt at this. In that setting we calculated for various sample sizes and showed that even with a total sample size of 30, , the study design had a power β = 68% assuming that the pAUC (0.1) ranking statistic was used for analysis. The data generating mechanism in that simulation, however, is very simple and is not based on a theoretically justifiable model. Sample size calculations cannot be used for practical application without such justification. Unfortunately, it is extremely unlikely that one can ever stipulate a simulation model for gene expression array data that is based on adequate biological theory and knowledge of laboratory processes.
n n
Ideally a set of pilot data would be available upon which to base a simulation. To illustrate, suppose that the ovarian cancer data represents a dataset from a pilot study. We based a second simulation study on these data. Specifically we resampled with replacement the entire data vector of gene expressions for n cancer tissues and normal tissues from the original dataset and determined P Table 3 displays for various choices of sample sizes. We see that a gene that in truth ranks in the top 10 according to the pAUC (0.1) measure is almost certainly selected with data from a study involving as few as 30 tissues, if the selection criterion is that its pAUC (0.1) statistic ranks in the top 100 in the study. A gene, truly in the top 50 is likely to be selected (β=91%) from a study using 25 cancer and 25 non-cancer tissues.
The power , 1 k , quantifies how likely a gene randomly selected from the top is likely to be ranked in the top . Table 3 also displays which is the probability that all
n n truly top-ranking genes will rank in the top when the experiment involving n and tissues is performed. These probabilities are much lower because the criterion to be met is more stringent. In order that all top 30 genes be likely to be selected it appears that at least 100 tissues
should be studied (P g (100│ 30)=84%).
)
In these simulations we only considered equal numbers of cases and controls. Unequal sample sizes could be chosen. It would be interesting to see if, in general, relatively more cases than controls are desirable and how this should in general relate to the relative variability of gene expressions in cases versus controls. Another aspect that we feel should be explored further relates to the likely over-optimism of the pilot data that we use for simulation. Efron and Tibshirani (1994, section 25.5) suggest some caution about plugging in parameters from a pilot study for power calculations and their concerns apply here too. One could add noise to the observed data in the simulations for more conservative sample size calculations.
Additional Design and Data Analysis Considerations
We have considered only the comparative design where assays for both the normal tissues and cancer tissues are performed, each using a common control tissue. 
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We have argued in section 2 that the mean difference { 
In summary, for the type of application we consider in this paper, we prefer the design that yields relative expression levels for both normals and cases instead of just the composite g Z . This design allows a full and flexible comparison of the two distributions, that for normal tissues yielding a reference distribution against which the cancer tissue distribution can be compared. Such is not achieved with the design that evaluates normals only within the assay for the cancer tissue.
Concluding Remarks
In this paper we have considered the identification of a subset of genes that are differentially expressed between two tissue types from a large pool of candidate genes.
The same statistical problem arises in experiments involving other recently developed http://biostats.bepress.com/uwbiostat/paper184 high throughput technologies. For example, protein mass spectrometry can be used to identify a set of proteins differentially expressed from amongst a large set of candidate proteins. Large arrays of tumor antigens are used to select a subset to which antibodies are differentially present in subjects with and without cancer. The concept of ranking genes using a statistical measure of discrimination between tissues, applies equally well to proteins in protein spectrometry and to antigens in tumor immunogenicity experiments.
Thus, our methods will also be useful in these settings.
We have emphasized that investigators must carefully choose the statistical measure for ranking the genes so that it fits the purpose of the experiment. For disease screening we have argued that biomarkers must be highly specific. This could be argued for other applications too, such as in the identification of treatment targets. Statistical measures such as the pAUC or ROC statistics are appealing when specificity is important. Dudoit et al (2002) use Zstat, the standardized difference in means, to rank genes. Efron et al (2000) also use a difference in means with a somewhat different standardization.
Their rationale for using these measures over others was not discussed. We have suggested the selection probability, , to quantify sampling variability and confidence in the gene ranking, and as the basis for sample size calculations. Dudoit et al (2000) use p-values for a related purpose. However, we find the interpretation of more compelling given the exploratory nature of the study. The purpose is not to test a null hypothesis about equal distributions of gene expression versus unequal distributions.
More importantly, the objective is to rank genes according to the extent of differential expression. Although the measures used by Dudoit et al (2000) and by Newton et al (2000) are statistics for testing a null hypothesis, they are used more in the same spirit as we use statistics, namely to rank genes according to the extent of differential expression. Efron et al (2000) consider two probabilities: a p-value, Prob {data at gene g | null hypothesis of equal expression}, and a Bayesian probability, Prob {gene g affected | data at gene g} = 1-P {equal expression | data at gene g}. Again, since many genes will be differentially expressed, probabilities relating to the null state of equal expression seem less compelling than ranking the extent of differential expression amongst the genes.
Moreover, Efron et al (2000) use the probabilities to rank the genes, whereas we use the selection probabilities only to quantify sampling variability in the rankings. is a function of these distributions it seems intuitive that the bootstrap estimate of P g (k) will be consistent.
However, it is likely that bootstrap or any data-based estimates of will be correlated with the data-based ordering of the gene. This correlation implies that if attention is restricted to a subset of genes that are observed to rank high say, then as a group their estimated selection probabilities will tend to be biased upwards. Efforts to reduce this bias would be worthwhile.
( )
The initial motivation for our research was to develop a strategy for sample size calculations. The strategy we propose is based on selection probabilities for informative genes, and is implemented with bootstrap simulation studies using pilot data. A similar strategy could be used for calculating sample sizes in studies that have the determination of gene clusters as the ultimate purpose. The single gene probabilities of Van der Laan and Bryan (2001) or some related construct could take the place of the selection probabilities in that sort of application.
Laboratory techniques for measuring gene expression with microarrays are certainly imperfect. Moreover, data processing procedures for calculating the relative expression values from the raw images data are evolving. The variability and biases in the derived values will surely impact on the gene rankings observed. It would be interesting to determine the extent of these impacts and if the use of ROC statistics can mitigate some of these problems because they are rank based. Hopefully, laboratory and data processing procedures will improve in the future, to alleviate related statistical concerns.
Although the identification of differentially expressed genes is the first objective, it is not the only objective of an exploratory gene expression study. In cancer research, it is recognized that cancer is a heterogeneous disease and that different unidentified subtypes may be characterized by unique sets of overexpressed genes. Thus, if a single gene doesn't completely discriminate cancer from non-cancer it may be possible that a small set of genes each flagging one subtype will. Statistical methods to identify such minimal subsets are needed. Ranking of different subsets of genes might draw on ideas presented
here. In addition, the identifications of clusters of genes, that is, genes that are over-or underexpressed in the same cancer tissues would be of interest. Biological insights into the pathways and pathogenesis of cancer would likely result. Some modifications of the plaid models (Lazzeroni and Owen, 2002) to include a baseline reference group of tissues (non-cancer in our case) might be useful for this purpose. partial AUC (.10) Figure 5 
